Figure 2.

Selection of EBOV-GP plasma samples and their abilities to bind EBOV-GP, EBOV-sGP, and SUDV-GP. (A) 145 samples from historic EBOV-GP ELISAs and EBOV neutralisation assays were correlated and analysed via linear regression. Samples greater than the axis limits were excluded from the graph for the purpose of clarity, but still included in the analysis. The LN cohort (red dots, n = 16) was selected using a neutralisation cut-off < 130 GMT (horizontal dotted line) and an antibody titre > 0.35 O.D. (vertical dotted line), with a maximum residual from the line of best fit (< -100 GMT). The N cohort (purple dots, n = 16) was selected using a neutralisation cut-off > 200 GMT and the closest possible residual to the line of best fit. (B) EBOV-GP, EBOV-sGP, and SUDV-GP conjugated beads were incubated with plasma from the LN (n = 18) or N (n = 18) cohorts and analysed via flow cytometry. Mean values are represented by horizontal dotted lines and significance determined using a Mann-Whitney U test. (C) A pairwise linear regression analysis was performed for each bead conjugate with LN (n = 18) and N (n = 18) plasma cohorts and the R² values for IgG binding were presented in the form of a heatmap. ** = significant (P < 0.01), ns, Not significant.